Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company focused on harnessing the body’s natural cancer-fighting abilities, announced an upcoming investor conference call. Scheduled for Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET, the call will feature a discussion of clinical data from the AFM24-102 trial. This trial combines Affimed’s AFM24 innate cell engager (ICE®) with atezolizumab to treat non-small cell lung cancer.
The call will be accessible via phone and webcast. The webcast can be found on the “Investors” page of Affimed’s website under “Webcasts” at . Dial-in details and a PIN number are available via this link
.
Note: To ensure timely participation, participants are encouraged to join 15 minutes prior to the scheduled start time. A replay of the webcast will be available at the same link for 30 days post-call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company dedicated to leveraging the innate immune system to combat cancer. Their innate cell engagers (ICE®), developed using their proprietary ROCK® platform, target and destroy various hematologic and solid tumors. These ICE® molecules are currently undergoing clinical trials as both monotherapy and combination therapy. Based in Mannheim, Germany, Affimed is driven by a team of experienced biotechnology and pharmaceutical professionals committed to improving cancer patient outcomes. More information on the company, its pipeline, and collaborations can be found at: .
Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail:
Tel.: +1 (917) 436-8102
